

# Abbreviations

<b>ADC</b>	antibody-drug conjugate	<b>MSI</b>	microsatellite instability
<b>AEs</b>	adverse events	<b>mut/Mb</b>	mutations per million bases
<b>ASCO</b>	American Society of Clinical Oncology	<b>NCCN</b>	National Comprehensive Cancer Network
<b>CC</b>	cervical cancer	<b>NK</b>	natural killer
<b>CCRT</b>	concurrent chemoradiotherapy	<b>NMPA</b>	China National Medical Products Administration
<b>CPS</b>	combined positive score	<b>ORR</b>	objective response rate
<b>CRs</b>	complete responses	<b>OS</b>	overall survival
<b>CTLA-4</b>	cytotoxic T-lymphocyte-associated protein 4	<b>PD-1</b>	programmed cell death-1
<b>DCR</b>	disease control rate	<b>PD-L1</b>	programmed cell death ligand-1
<b>DCs</b>	dendritic cells	<b>PFS</b>	progression-free survival
<b>DLTs</b>	dose-limiting toxicities	<b>PRs</b>	partial responses
<b>DMFS</b>	distance metastasis-free survival	<b>R/M</b>	recurrent/metastatic
<b>DOR</b>	duration of response	<b>SCC</b>	squamous cell carcinoma
<b>FDA</b>	U.S. Food and Drug Administration	<b>SDs</b>	stable disease
<b>FIGO</b>	International Federation of Gynecology and Obstetrics	<b>SGO</b>	Society for Gynecologic Oncology
<b>HPV</b>	human papillomavirus	<b>TGF-<math>\beta</math>RII</b>	transforming growth factor- $\beta$ receptor II
<b>hrHPVs</b>	high-risk HPV subtypes	<b>TIGIT</b>	T cell immunoglobulin and ITIM domains
<b>ICB</b>	immune checkpoint blockade	<b>TILs</b>	tumor-infiltrating lymphocytes
<b>ICOS</b>	inducible T-cell costimulator	<b>TMB</b>	tumor mutational burden
<b>IDO1</b>	indoleamine 2, 3-dioxygenase 1	<b>TME</b>	tumor microenvironment
<b>irAE</b>	immune-related adverse events	<b>TRAEs</b>	treatment-related adverse events
<b>LACC</b>	locally advanced cervical cancer	<b>TV</b>	Tisotumab vedotin
<b>mAb</b>	monoclonal antibody	<b>VEGFR-2</b>	vascular endothelial growth factor receptor-2